[1]
|
Soerjomataram, I. and Bray, F. (2021) Planning for Tomorrow: Global Cancer Incidence and the Role of Prevention 2020-2070. Nature Reviews Clinical Oncology, 18, 663-672. https://doi.org/10.1038/s41571-021-00514-z
|
[2]
|
Hurvitz, S.A., Martin, M., Symmans, W.F., Jung, K.H., Huang, C.-S., Thompson, A.M., et al. (2018) Neoadjuvant Trastuzumab, Pertuzumab, and Chemotherapy versus Trastuzumab Emtansine plus Pertuzumab in Patients with HER2-Positive Breast Cancer (KRISTINE): A Randomised, Open-Label, Multicentre, Phase 3 Trial. The Lancet Oncology, 19, 115-126. https://doi.org/10.1016/S1470-2045(17)30716-7
|
[3]
|
Von Minckwitz, G., Procter, M., De Azambuja, E., Zardavas, D., Benyunes, M., Viale, G., et al. (2017) Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. The New England Journal of Medicine, 377, 122-131.
https://doi.org/10.1056/NEJMoa1703643
|
[4]
|
Pernas, S. and Tolaney, S.M. (2022) Clinical Trial Data and Emerg-ing Strategies: HER2-Positive Breast Cancer. Breast Cancer Research and Treatment, 193, 281-291. https://doi.org/10.1007/s10549-022-06575-7
|
[5]
|
Najjar, M.K., Manore, S.G., Regua, A.T. and Lo, H.-W. (2022) Antibody-Drug Conjugates for the Treatment of HER2- Positive Breast Cancer. Genes, 13, Article No. 2065. https://doi.org/10.3390/genes13112065
|
[6]
|
Lopez-Tarruella, S., Echavarria, I., Jerez, Y., Herrero, B., Gamez, S. and Martin, M. (2022) How We Treat HR-Positive, HER2-Negative Early Breast Cancer. Future Oncology, 18, 1003-1022. https://doi.org/10.2217/fon-2021-0668
|
[7]
|
Jerusalem, G., Lancellotti, P. and Kim, S.-B. (2019) HER2+ Breast Cancer Treatment and Cardiotoxicity: Monitoring and Management. Breast Cancer Research and Treat-ment, 177, 237-250. https://doi.org/10.1007/s10549-019-05303-y
|
[8]
|
Chan, A., Moy, B., Mansi, J., Ejlertsen, B., Holmes, F.A., Chia, S., et al. (2021) Final Efficacy Results of Neratinib in HER2-Positive Hormone Receptor-Positive Early-Stage Breast Cancer from the Phase III ExteNET Trial. Clinical Breast Cancer, 21, 80-91.E7. https://doi.org/10.1016/j.clbc.2020.09.014
|
[9]
|
Swain, S.M., Shastry, M. and Hamilton, E. (2023) Targeting HER2-Positive Breast Cancer: Advances and Future Directions. Nature Reviews Drug Discovery, 22, 101-126. https://doi.org/10.1038/s41573-022-00579-0
|
[10]
|
Nader-Marta, G., Martins-Branco, D. and De Azambuja, E. (2022) How We Treat Patients with Metastatic HER2- Positive Breast Cancer. ESMO Open, 7, Article ID: 100343. https://doi.org/10.1016/j.esmoop.2021.100343
|
[11]
|
Seidman, A., Hudis, C., Pierri, M.K., Shak, S., Paton, V., Ashby, M., et al. (2002) Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience. Journal of Clinical Oncolo-gy, 20, 1215-1221.
|
[12]
|
De Azambuja, E., Procter, M.J., Van Veldhuisen, D.J., Agbor-Tarh, D., Metzger-Filho, O., Steinseifer, J., et al. (2014) Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01). JCO, 32, 2159-2165. https://doi.org/10.1200/JCO.2013.53.9288
|
[13]
|
Advani, P.P., Ballman, K.V., Dockter, T.J., Colon-Otero, G. and Perez, E.A. (2016) Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial. JCO, 34, 581-587.
https://doi.org/10.1200/JCO.2015.61.8413
|
[14]
|
Romond, E.H., Jeong, J.-H., Rastogi, P., Swain, S.M., Geyer, C.E., Ewer, M.S., et al. (2012) Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) with ACP plus Trastuzumab as Adjuvant Therapy for Patients with Node-Positive, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. JCO, 30, 3792-3799.
https://doi.org/10.1200/JCO.2011.40.0010
|
[15]
|
Fiúza, M. (2009) Cardiotoxicity Associated with Trastuzumab Treatment of HER2+ Breast Cancer. Advances in Therapy, 26, 9-17. https://doi.org/10.1007/s12325-009-0048-z
|
[16]
|
Bowles, E.J.A., Wellman, R., Feigelson, H.S., Onitilo, A.A., Freedman, A.N., Delate, T., et al. (2012) Risk of Heart Failure in Breast Cancer Patients after Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study. JNCI Journal of the National Cancer Institute, 104, 1293-1305. https://doi.org/10.1093/jnci/djs317
|
[17]
|
Addetia, K. and DeCara, J.M. (2016) Cardiac Complications of HER2-Targeted Therapies in Breast Cancer. Current Treatment Options in Cardiovascular Medicine, 18, Article No. 36. https://doi.org/10.1007/s11936-016-0458-6
|
[18]
|
Ishii, K., Morii, N. and Yamashiro, H. (2019) Pertuzumab in the Treatment of HER2-Positive Breast Cancer: An Evidence-Based Review of Its Safety, Efficacy, and Place in Therapy. Core Evidence, 14, 51-70.
https://doi.org/10.2147/CE.S217848
|
[19]
|
Sendur, M.A., Aksoy, S. and Altundag, K. (2015) Pertuzumab-Induced Cardiotoxicity: Safety Compared with Trastuzumab. Future Oncology, 11, 13-15. https://doi.org/10.2217/fon.14.184
|
[20]
|
Swain, S.M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., et al. (2015) Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer. The New England Journal of Medicine, 372, 724-734.
https://doi.org/10.1056/NEJMoa1413513
|
[21]
|
Lees, C., Yazdan-Ashoori, P., Jerzak, K.J. and Gandhi, S. (2019) Takotsubo Cardiomyopathy during Anti-HER2 Therapy for Metastatic Breast Cancer. The Oncologist, 24, E80-E82. https://doi.org/10.1634/theoncologist.2018-0285
|
[22]
|
Rugo, H.S., Im, S.-A., Cardoso, F., Cortés, J., Curigliano, G., Musolino, A., et al. (2021) Efficacy of Margetuximab vs Trastuzumab in Patients with Pretreated ERBB2-Positive Ad-vanced Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncology, 7, 573-584. https://doi.org/10.1001/jamaoncol.2020.7932
|
[23]
|
Markham, A. (2021) Margetuximab: First Approval. Drugs, 81, 599-604. https://doi.org/10.1007/s40265-021-01485-2
|
[24]
|
Gradishar, W.J., O’Regan, R., Rimawi, M.F., Nordstrom, J.L., Rosales, M.K. and Rugo, H.S. (2023) Margetuximab in HER2-Positive Metastatic Breast Cancer. Fu-ture Oncology, 19, 1099-1112. https://doi.org/10.2217/fon-2022-1040
|
[25]
|
Deeks, E.D. (2017) Neratinib: First Global Approval. Drugs, 77, 1695-1704.
https://doi.org/10.1007/s40265-017-0811-4
|
[26]
|
Xuhong, J.-C., Qi, X-W., Zhang, Y. and Jiang, J. (2019) Mecha-nism, Safety and Efficacy of Three Tyrosine Kinase Inhibitors Lapatinib, Neratinib and Pyrotinib in HER2-Positive Breast Cancer. American Journal of Cancer Research, 9, 2103-2119.
|
[27]
|
Ma, F., Ouyang, Q., Li, W., Jiang, Z., Tong, Z., Liu, Y., et al. (2019) Pyrotinib or Lapatinib Combined with Capecitabine in HER2-Positive Metastatic Breast Cancer with Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study. JCO, 37, 2610-2619. https://doi.org/10.1200/JCO.19.00108
|
[28]
|
Lee, A. (2020) Tucatinib: First Approval. Drugs, 80, 1033-1038. https://doi.org/10.1007/s40265-020-01340-w
|
[29]
|
Murthy, R.K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S.A., et al. (2020) Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. The New England Journal of Medicine, 382, 597-609.
https://doi.org/10.1056/NEJMoa1914609
|
[30]
|
Hunter, F.W., Barker, H.R., Lipert, B., Rothé, F., Gebhart, G., Pic-cart-Gebhart, M.J., et al. (2020) Mechanisms of Resistance to Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer. British Journal of Cancer, 122, 603- 612. https://doi.org/10.1038/s41416-019-0635-y
|
[31]
|
Pondé, N., Ameye, L., Lambertini, M., Paesmans, M., Piccart, M. and De Azambuja, E. (2020) Trastuzumab Emtansine (T-DM1)-Associated Cardiotoxicity: Pooled Analysis in Advanced HER2-Positive Breast Cancer. European Journal of Cancer, 126, 65-73. https://doi.org/10.1016/j.ejca.2019.11.023
|
[32]
|
Narayan, P., Osgood, C.L., Singh, H., Chiu, H.-J., Ricks, T.K., Chiu, Y., Chow, E., et al. (2021) FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer. Clinical Cancer Research, 27, 4478-4485. https://doi.org/10.1158/1078-0432.CCR-20-4557
|
[33]
|
Soares, L.R., Vilbert, M., Rosa, V.D.L., Oliveira, J.L., Deus, M.M. and Freitas-Junior, R. (2023) Incidence of Interstitial Lung Disease and Cardiotoxicity with Trastuzumab Derux-tecan in Breast Cancer Patients: A Systematic Review and Single-Arm Meta-Analysis. ESMO Open, 8, Article ID: 101613. https://doi.org/10.1016/j.esmoop.2023.101613
|
[34]
|
Curigliano, G., Cardinale, D., Suter, T., Plataniotis, G., De Azambuja, E., Sandri, M.T., et al. (2012) Cardiovascular Toxicity Induced by Chemotherapy, Targeted Agents and Radiotherapy: ESMO Clinical Practice Guidelines. Annals of Oncology, 23, Vii155-Vii166. https://doi.org/10.1093/annonc/mds293
|
[35]
|
Thygesen, K., Alpert, J.S., Jaffe, A.S., Chaitman, B.R., Bax, J.J., Morrow, D.A., et al. (2018) Fourth Universal Definition of Myocardial Infarction (2018). Circulation, 138, e618-e651. https://doi.org/10.1161/CIR.0000000000000617
|